2018 Second Quarter and R&D update
We announced our second quarter 2018 results on Wednesday 25 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our performance and financial outlook, and Hal Barron, Chief Scientific Officer and President, R&D, presented our R&D update.
- Q2 2018 results and R&D update announcement PDF - 1.0MB
- Q2 2018 slides - Emma Walmsley PDF - 495.7KB
- Q2 2018 slides - Simon Dingemans PDF - 131.7KB
- R&D update slides - Hal Barron PDF - 1.9MB
- Q2 2018 results transcript - Part 1 PDF - 188.4KB
- Q2 2018 results transcript - Part 2 PDF - 242.3KB
- Q2 2018 results infographic PDF - 556.7KB
- Q2 2018 US dollar translation PDF - 131.6KB
- Q2 2018 pre announcement aide memoire PDF - 742.2KB
2014 First Quarter
Simon Dingemans, CFO, discusses our first quarter results 2014.
2013 Fourth Quarter - released 05 February 2014
Sir Andrew Witty, CEO, and Simon Dingemans, CFO, discuss our full year 2013 results.
- Q4 2013 results announcement PDF - 272.9KB
- Q4 2013 analyst slide presentation PDF - 2.0MB
- Q4 2013 analyst presentation transcript PDF - 61.3KB
- Q4 2013 analyst investor call transcript PDF - 196.7KB
- Q4 2013 actual growth schedules PDF - 195.2KB
- Q4 2013 US dollar translation PDF - 135.9KB
- Q4 2013 pre announcement aide memoire PDF - 848.7KB
2013 Third Quarter - released 23 October 2013
Simon Dingemans, CFO, discusses our third quarter results 2013.
2013 Second Quarter - released 24 July 2013
Simon Dingemans, CFO, discusses our second quarter results 2013.
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III